| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H24N2OS |
| Molecular Weight | 340.482 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCCSC1=C(NC(=O)\C=C\C2=CC=CC=C2)C=CC=C1
InChI
InChIKey=RSUVYMGADVXGOU-BUHFOSPRSA-N
InChI=1S/C20H24N2OS/c1-22(2)15-8-16-24-19-12-7-6-11-18(19)21-20(23)14-13-17-9-4-3-5-10-17/h3-7,9-14H,8,15-16H2,1-2H3,(H,21,23)/b14-13+
| Molecular Formula | C20H24N2OS |
| Molecular Weight | 340.482 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
Cinanserin is a 5-hydroxytryptamine receptor antagonist; it shows a low affinity to 5-HT2b binding sites and a 4-to 10-fold lower affinity to 5-HT2c receptor binding sites than for 5-HT2a sites. Nevertheless, at concentrations normally used 5-HT2c receptor blocking effects are still likely. Experiments on animal have shown that intravenous administration of cinanserin significantly reduces systemic burn edema and leukocyte-endothelial interactions.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
Patents
Sample Use Guides
Binding of both cinanserin and its hydrochloride to bacterially expressed 3C-like proteinase (3CLpro) of syndrome-associated coronavirus (SARS-CoV) and the related human coronavirus 229E (HCoV-229E) was demonstrated by surface plasmon resonance technology. The antiviral activity of cinanserin was further evaluated in tissue culture assays, namely, a replicon system based on HCoV-229E and quantitative test assays with infectious SARS-CoV and HCoV-229E. The level of virus RNA and infectious particles was reduced by up to 4 log units, with IC50 values ranging from 19 to 34 microM.
